Physician profile
Katy W Minga
NPI 1609271576
$10,187.06
in general payments reported to CMS, 2019-2025
33 companies · $2,848 in 2025
The $2,848 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $729 · 2022: $1,701 · 2023: $2,716 · 2024: $2,193 · 2025: $2,848.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,640 · Education: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,640.01 |
| Education | $116.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,256.63 | 2021-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Inspire Medical Systems, INC. | $1,187.44 | 2023-2025 | Inspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,154.59 | 2021-2025 | Ofev, Jascayd, Spiriva Respimat |
| Astrazeneca Pharmaceuticals LP | $940.96 | 2021-2025 | Airsupra, Breztri, Brilinta |
| Harmony Biosciences LLC | $876.26 | 2021-2025 | Wakix |
| Regeneron Healthcare Solutions, INC. | $683.29 | 2022-2025 | Dupixent |
| Genzyme Corporation | $674.20 | 2021-2025 | |
| Actelion Pharmaceuticals US, INC. | $481.96 | 2021-2025 | Opsumit, Uptravi, Opsynvi |
| Mylan Specialty L.P. | $431.45 | 2022-2024 | Yupelri |
| Insmed, INC. | $349.55 | 2021-2025 | Arikayce |
| Grifols USA, LLC | $318.70 | 2022-2025 | Prolastin-C Liquid |
| Mallinckrodt Hospital Products INC. | $303.76 | 2022-2025 | Acthar |
| Viatris Specialty LLC | $296.01 | 2025 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $213.37 | 2021-2025 | Glassia |
| Bayer Healthcare Pharmaceuticals INC. | $165.07 | 2022-2024 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $149.49 | 2023-2024 | Hillrom - Life 2000 Ventilation System, Hillrom - Monarch Airway Clearance System |
| Verona Pharma, INC. | $144.24 | 2025 | Ohtuvayre |
| Merck Sharp & Dohme LLC | $101.53 | 2022-2025 | Zerbaxa, Recarbrio |
| United Therapeutics Corporation | $86.63 | 2021-2023 | Tyvaso |
| Fisher & Paykel Healthcare INC | $59.51 | 2022-2024 | Fisher & Paykel Healthcare |
| Ani Pharmaceuticals, INC. | $49.17 | 2023-2025 | Purified Cortrophin Gel |
| Genentech USA, INC. | $43.79 | 2022-2023 | Xolair |
| Breas Medical, INC. | $32.46 | 2025 | Vivo 45 Ls |
| Vbi Vaccine (Delaware) INC. | $28.11 | 2022 | |
| Janssen Pharmaceuticals, INC | $24.52 | 2021 | |
| Bioxcel Therapeutics, INC. | $21.63 | 2023 | Igalmi |
| Ambu INC. | $20.19 | 2022 | |
| Si-Bone, INC. | $18.71 | 2022 | |
| Chiesi USA, INC. | $16.58 | 2022 | |
| Nevro Corp. | $15.05 | 2024 | Senza |
| Pfizer INC. | $15.00 | 2024 | |
| Jazz Pharmaceuticals INC. | $13.92 | 2021 | |
| Gilead Sciences, INC. | $13.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katy Minga listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.